Articles

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 – Immuno-Oncology

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 – Immuno-Oncology

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 – Immuno-Oncology

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Page 140 of 147